Table 2.
Characteristics of Patients with Transmitted Drug Resistance Mutations
| Surveillance drug resistance mutationse | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patienta | Cluster | Sexb | Age (years) | Weeks of infectionc | Country of origind | Transmission risk groupe | CD4 (cells/mm3) | Plasma HIV-1 RNA (copies×104/ml) | Subtype | NRTI | NNRTI | PI |
| GR013 | I | M | 29 | 1 | Greece | MSM | 844 | 4.5 | A1 | T215C | Y181C | — |
| GR015 | I | M | 30 | 4 | Greece | MSM | 583 | 12.2 | A1 | T215C | Y181C | — |
| GR061 | I | M | 28 | 2 | Greece | MSM | 1086 | 0.2 | A1 | T215C | Y181C | — |
| GR075 | I | M | 38 | 1 | Greece | MSM | 633 | 1.3 | A1 | T215C | Y181C | — |
| GR105 | I | M | 35 | 2 | Albania | MSM | 350 | 33.0 | A1 | T215C | Y181C | — |
| GR117 | I | M | 48 | 3 | Greece | HSX | 154 | 23.0 | A1 | T215C | Y181C | — |
| GR144 | I | M | 36 | 2 | Greece | MSM | 305 | 109.0 | A1 | T215C | Y181C | — |
| GR146 | I | M | 50 | 2 | Greece | MSM | 496 | 12.0 | A1 | T215C | Y181C | — |
| GR083 | II | M | 32 | 3 | Greece | MSM | 228 | 10.0 | A1 | T215S | K103N | — |
| GR087 | II | M | 22 | 2 | Greece | MSM | 481 | 2.8 | A1 | T215S | K103N | N88S |
| GR107 | III | M | 25 | 1 | Greece | HSX | 238 | 1.5 | A1 | — | K103N | — |
| GR136 | III | M | 26 | 4 | Greece | MSM | 899 | 0.2 | A1 | — | K103N | — |
| GR143 | III | F | 31 | 8 | Russia | HSX | 382 | 0.7 | A1 | — | K103N | — |
| GR062 | IV | F | 38 | 2 | South Africa | HSX | 38 | 16.6 | C | — | Y181I | — |
| GR063 | IV | M | 40 | 2 | Greece | HSX | 495 | 0.3 | C | D67N | Y181I | — |
| GR033 | — | M | 29 | 12 | Greece | MSM | 378 | 16.2 | B | — | G190A | — |
| GR098 | M | 30 | 3 | Greece | MSM | 438 | 10.2 | A1 | T215C | Y181C | — | |
a
Indicates the laboratory code for each study subject.
b
F, female; M, male.
c
Indicates the duration from the first known positive HIV antibody test.
d
Country of birth of the study subjects. N/A, not available.
e
Defined according to the published list of mutations for surveillance to transmitted drug resistance as recommended by the World Health Organization.8
MSM, men who have sex with men; HSX, heterosexual contact; IDU, intravenous drug user, N/A, not available; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.